Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral therapy
protease inhibitor |
| gptkbp:approvalYear |
1999
|
| gptkbp:ATCCode |
J05AE05
|
| gptkbp:brand |
gptkb:Agenerase
|
| gptkbp:CASNumber |
161814-49-9
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:discontinued |
2004
|
| gptkbp:eliminationHalfLife |
7-10 hours
|
| gptkbp:hasMolecularFormula |
C25H35N3O6S
|
| https://www.w3.org/2000/01/rdf-schema#label |
amprenavir
|
| gptkbp:KEGGID |
D00299
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinBinding |
90%
|
| gptkbp:PubChem_CID |
65016
CHEMBL121 DB00701 58536 |
| gptkbp:replacedBy |
fosamprenavir
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea rash oral paresthesia |
| gptkbp:status |
discontinued
|
| gptkbp:UNII |
Q3JTX2Q7TU
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Fosamprenavir
|
| gptkbp:bfsLayer |
7
|